Industry Strength Score
55/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
LISATA THERAPEUTICS INC (LSTA) Stock Price & Overview
NASDAQ:LSTA • US1280583022
Current stock price
3.22 USD
+0.02 (+0.63%)
Last:
The current stock price of LSTA is 3.22 USD. Today LSTA is up by 0.63%. In the past month the price decreased by -35.73%. In the past year, price increased by 33.61%.
LSTA Key Statistics
52-Week Range1.81 - 5.07
Current LSTA stock price positioned within its 52-week range.
1-Month Range2.75 - 5.03
Current LSTA stock price positioned within its 1-month range.
- Market Cap
- 29.077M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.91
- Dividend Yield
- N/A
LSTA Stock Performance
Today
+0.63%
1 Week
-5.85%
1 Month
-35.73%
3 Months
-30.45%
Longer-term
6 Months +15.41%
1 Year +33.61%
2 Years +17.95%
3 Years -0.92%
5 Years N/A
10 Years N/A
LSTA Stock Chart
LSTA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to LSTA. When comparing the yearly performance of all stocks, LSTA turns out to be only a medium performer in the overall market: it outperformed 44.23% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
LSTA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LSTA. LSTA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
LSTA Earnings
Next Earnings DateMay 6, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
LSTA Forecast & Estimates
9 analysts have analysed LSTA and the average price target is 11.56 USD. This implies a price increase of 259.01% is expected in the next year compared to the current price of 3.22.
Analysts
Analysts82.22
Price Target11.56 (259.01%)
EPS Next Y58.71%
Revenue Next YearN/A
LSTA Financial Highlights
Over the last trailing twelve months LSTA reported a non-GAAP Earnings per Share(EPS) of -1.91. The EPS increased by 20.31% compared to the year before.
Income Statements
Revenue(TTM)170.00K
Net Income(TTM)-16.59M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -93.47% | ||
| ROE | -111.65% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%38.88%
Sales Q2Q%-90%
EPS 1Y (TTM)20.31%
Revenue 1Y (TTM)-83%
LSTA Ownership
Ownership
Inst Owners7.86%
Shares9.03M
Float7.07M
Ins Owners9.51%
Short Float %0.73%
Short Ratio0.61
LSTA Industry Overview
LSTA operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
44%
Outperformed 44% of sub-industries
6 Month Rank
31%
Outperformed 31% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.8%
- New Lows
- 3.9%
- Average ROE
- 48.2%
- Average Profit Margin
- 20.9%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.1
- Average Fwd P/E
- 22.4
- Average Debt/Equity
- 2.1
LSTA Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.88 | 360.632B | ||
| AMGN | AMGEN INC | 15.04 | 182.426B | ||
| GILD | GILEAD SCIENCES INC | 14.47 | 159.919B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.75 | 107.655B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.55 | 72.562B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.05 | 40.188B | ||
| INSM | INSMED INC | N/A | 29.146B | ||
| BIIB | BIOGEN INC | 11.73 | 28.527B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.853B | ||
| NTRA | NATERA INC | N/A | 27.602B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.59 | 25.03B | ||
| INCY | INCYTE CORP | 10.86 | 19.722B | ||
| MRNA | MODERNA INC | N/A | 18.132B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LSTA
Company Profile
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 21 full-time employees. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.
Company Info
IPO: 1995-11-03
LISATA THERAPEUTICS INC
110 Allen Road, Second Floor
Basking Ridge NEW JERSEY US
Employees: 21
Phone: 19082292590
LISATA THERAPEUTICS INC / LSTA FAQ
What does LISATA THERAPEUTICS INC do?
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 21 full-time employees. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.
What is the current price of LSTA stock?
The current stock price of LSTA is 3.22 USD. The price increased by 0.63% in the last trading session.
Does LSTA stock pay dividends?
LSTA does not pay a dividend.
What is the ChartMill rating of LISATA THERAPEUTICS INC stock?
LSTA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is LISATA THERAPEUTICS INC (LSTA) stock traded?
LSTA stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for LISATA THERAPEUTICS INC?
LISATA THERAPEUTICS INC (LSTA) operates in the Health Care sector and the Biotechnology industry.
Is LISATA THERAPEUTICS INC (LSTA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LSTA.